Jade Biosciences, Inc.

JBIOSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1798749

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$31.2M	$64.2M	$38.6M	$15.0M	$7.9M
Operating Expenses	$35.5M	$81.4M	$53.2M	$23.0M	$8.9M
Operating Income (Loss)	-$35.5M	-$81.4M	-$53.2M	-$23.0M	-$8.9M
Interest Expense	—	—	—	—	$75.0K
Nonoperating Income (Expense)	-$11.4M	$5.9M	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$47.0M	-$75.5M	-$51.5M	-$23.0M	-$9.6M
Income Tax Expense (Benefit)	$0.00	$56.0K	$25.0K	$3.0K	$3.0K
Net Income (Loss) Attributable to Parent	-$47.0M	-$75.5M	-$51.5M	-$23.0M	-$9.6M
Earnings Per Share, Basic	-$14.89	-$2.87	-$2.10	-$1.87	—
Earnings Per Share, Diluted	-$14.89	-$2.87	-$2.10	-$1.87	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$72.8M	$127.4M	$135.3M	$175.4M	$4.7M
Assets, Current	$69.7M	$124.2M	$131.5M	$174.3M	$4.7M
Cash and Cash Equivalents, at Carrying Value	$69.4M	$23.5M	$22.4M	$54.2M	$4.6M
Liabilities	$119.6M	$18.0M	$8.6M	$2.9M	$1.8M
Liabilities, Current	$12.0M	$17.6M	$7.8M	$2.5M	$1.8M
Accounts Payable, Current	$1.3M	$2.4M	$2.6M	$1.2M	$618.0K
Stockholders' Equity Attributable to Parent	$1.0K	$126.7M	$172.4M	-$13.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$22.6M	-$56.8M	-$39.1M	-$27.4M	-$7.9M
Net Cash Provided by (Used in) Investing Activities	-$247.0M	$11.9M	$6.9M	-$113.4M	-$113.4M
Net Cash Provided by (Used in) Financing Activities	$92.0M	$46.0M	$396.0K	$190.5M	$8.9M
Payments to Acquire Property, Plant, and Equipment	$196.0K	$142.0K	$195.0K	$181.0K	$181.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)